139 related articles for article (PubMed ID: 31058556)
1. The first case of elderly
Takeda R; Yokoyama K; Ogawa M; Kawamata T; Fukuyama T; Kondoh K; Takei T; Nakamura S; Ito M; Yusa N; Shimizu E; Ohno N; Uchimaru K; Yamaguchi R; Imoto S; Miyano S; Tojo A
Leuk Lymphoma; 2019 Nov; 60(11):2821-2824. PubMed ID: 31058556
[No Abstract] [Full Text] [Related]
2. Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL.
Lejman M; Włodarczyk M; Zawitkowska J; Kowalczyk JR
BMC Med Genomics; 2020 Apr; 13(1):58. PubMed ID: 32245383
[TBL] [Abstract][Full Text] [Related]
3. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
4. Durable remissions in
Mouttet B; Vinti L; Ancliff P; Bodmer N; Brethon B; Cario G; Chen-Santel C; Elitzur S; Hazar V; Kunz J; Möricke A; Stein J; Vora A; Yaman Y; Schrappe M; Anak S; Baruche A; Locatelli F; von Stackelberg A; Stanulla M; Bourquin JP
Haematologica; 2019 Jun; 104(6):e244-e247. PubMed ID: 30765470
[No Abstract] [Full Text] [Related]
5. NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia.
Kachroo P; Szymczak S; Heinsen FA; Forster M; Bethune J; Hemmrich-Stanisak G; Baker L; Schrappe M; Stanulla M; Franke A
Epigenomics; 2018 Feb; 10(2):133-147. PubMed ID: 29334255
[TBL] [Abstract][Full Text] [Related]
6. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1.
Jeha S; Pei D; Raimondi SC; Onciu M; Campana D; Cheng C; Sandlund JT; Ribeiro RC; Rubnitz JE; Howard SC; Downing JR; Evans WE; Relling MV; Pui CH
Leukemia; 2009 Aug; 23(8):1406-9. PubMed ID: 19282835
[TBL] [Abstract][Full Text] [Related]
7. Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with
Aldoss I; Pullarkat V
Leuk Lymphoma; 2019 Nov; 60(11):2832-2834. PubMed ID: 31014138
[No Abstract] [Full Text] [Related]
8. Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.
Heilmann AM; Schrock AB; He J; Nahas M; Curran K; Shukla N; Cramer S; Draper L; Verma A; Erlich R; Ross J; Stephens P; Miller VA; Ali SM; Verglio JA; Tallman MS; Mughal TI
Leukemia; 2017 Sep; 31(9):1989-1992. PubMed ID: 28552906
[No Abstract] [Full Text] [Related]
9. Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
Perwein T; Strehl S; König M; Lackner H; Panzer-Grümayer R; Mann G; Attarbaschi A; Urban EC; Haas OA
Haematologica; 2016 Aug; 101(8):e332-5. PubMed ID: 27125982
[No Abstract] [Full Text] [Related]
10. B-lymphoblastic lymphoma with
Kubota-Tanaka M; Osumi T; Miura S; Tsujimoto H; Imamura T; Nishimura A; Oki K; Nakamura K; Miyamoto S; Inoue K; Inoue M; Kamiya T; Yanagimachi M; Okano T; Mitsuiki N; Isoda T; Imai K; Kanegane H; Morio T; Kounami S; Endo M; Kato M; Takagi M
Haematologica; 2019 Jan; 104(1):e35-e37. PubMed ID: 30262566
[No Abstract] [Full Text] [Related]
11. A novel KMT2A-ACTN2 fusion in infant B-cell acute lymphoblastic leukemia.
Yoshida M; Nakabayashi K; Ogata-Kawata H; Osumi T; Tsujimoto SI; Shirai R; Yoshida K; Okamura K; Matsumoto K; Kiyokawa N; Tomizawa D; Hata K; Kato M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27821. PubMed ID: 31115144
[No Abstract] [Full Text] [Related]
12. High RASD1 transcript levels at diagnosis predicted poor survival in adult B-cell acute lymphoblastic leukemia patients.
Wang S; Wang C; Wang W; Hao Q; Liu Y
Leuk Res; 2019 May; 80():26-32. PubMed ID: 30925311
[TBL] [Abstract][Full Text] [Related]
13. Emergence of a prominent myeloid clone in a ZNF384-rearranged B-cell precursor acute lymphoblastic leukaemia post-corticosteroid pre-phase therapy.
Kapadia AB; Sreedharanunni S; Muhammed S; Karmakar I; Rana S; Sharma P; Sachdeva MUS; Trehan A
Pediatr Blood Cancer; 2020 Dec; 67(12):e28513. PubMed ID: 32686312
[No Abstract] [Full Text] [Related]
14. Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
Wouters Y; Nevejan L; Louwagie A; Devos H; Dewaele B; Selleslag D; Michaux L
Br J Haematol; 2021 Feb; 192(4):e112-e115. PubMed ID: 33502001
[No Abstract] [Full Text] [Related]
15. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
[TBL] [Abstract][Full Text] [Related]
16. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
Fischer U; Forster M; Rinaldi A; Risch T; Sungalee S; Warnatz HJ; Bornhauser B; Gombert M; Kratsch C; Stütz AM; Sultan M; Tchinda J; Worth CL; Amstislavskiy V; Badarinarayan N; Baruchel A; Bartram T; Basso G; Canpolat C; Cario G; Cavé H; Dakaj D; Delorenzi M; Dobay MP; Eckert C; Ellinghaus E; Eugster S; Frismantas V; Ginzel S; Haas OA; Heidenreich O; Hemmrich-Stanisak G; Hezaveh K; Höll JI; Hornhardt S; Husemann P; Kachroo P; Kratz CP; Te Kronnie G; Marovca B; Niggli F; McHardy AC; Moorman AV; Panzer-Grümayer R; Petersen BS; Raeder B; Ralser M; Rosenstiel P; Schäfer D; Schrappe M; Schreiber S; Schütte M; Stade B; Thiele R; von der Weid N; Vora A; Zaliova M; Zhang L; Zichner T; Zimmermann M; Lehrach H; Borkhardt A; Bourquin JP; Franke A; Korbel JO; Stanulla M; Yaspo ML
Nat Genet; 2015 Sep; 47(9):1020-1029. PubMed ID: 26214592
[TBL] [Abstract][Full Text] [Related]
17. Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.
Schewe DM; Lenk L; Vogiatzi F; Winterberg D; Rademacher AV; Buchmann S; Henry D; Bergmann AK; Cario G; Cox MC
Blood Adv; 2019 Nov; 3(22):3499-3502. PubMed ID: 31725893
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Tutor O; Díaz MA; Ramírez M; Algara P; Madero L; Martínez P
Leuk Res; 2002 Sep; 26(9):817-20. PubMed ID: 12127556
[TBL] [Abstract][Full Text] [Related]
19. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
[No Abstract] [Full Text] [Related]
20. Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia.
Germano G; Pigazzi M; del Giudice L; Campo Dell'Orto M; Spinelli M; Zangrando A; Paolucci P; Ladogana S; Basso G
Haematologica; 2006 May; 91(5 Suppl):ECR09. PubMed ID: 16709517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
